Advancements in the Management of R/R AML: ASH 2024 - Episode 2
Treatment Goals and Unmet Needs in R/R AML
Panelists discuss how achieving responses with second-line treatment options after venetoclax-based regimens remains challenging, and explore strategies for bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients who relapse post venetoclax while also addressing the evolving management of patients following transplant.
Video content above is prompted by the following:
- Briefly comment on your clinical experience with the difficulty achieving responses with the currently available second line and beyond treatment options after patients are treated with venetoclax plus azacitidine (or decitabine).
- How do current therapies meet the needs of patients post-venetoclax failure?
- How often are you able to bring your patients to allo-HSCT once they relapse post venetoclax? How are utilizing the currently available R/R options as bridging therapy to allo-HSCT?
- How are you managing patients following a transplant? Do you see this changing in the future?
Related Content:
